|
The low affinity activating receptor CD16, is expressed on macrophages, natural killer cells and other immune effector cells. Stimulation of CD16 though engagement via the Fc regions of complexed antibodies triggers activation of effector cell functions. MacroGenics believes that prevention of CD16/Fc engagement is an effective means to treat antibody mediated autoimmune diseases such as rheumatoid arthritis, lupus, and idiopathic thrombocytopenic purpura (ITP). MacroGenics developed a humanized antibody that binds to CD16 receptor directly thereby blocking access to the Fc region that would normally engage and activate CD16. This product, GMA161, is being developed by Genzyme Corporation.
|
